CLICK HERE to learn more about Kineta's reverse merger with NASDAQ listed Yumanity Therapeutics (YMTX) announcement
Kineta Inc.
  • about
    • company
    • team
    • board
    • SAB
  • platform
  • pipeline
    • KVA12.1
    • CD27
    • KCP506
    • LHF535
  • partnering
  • investors
  • news
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
logo

Mark Middleton, MD PhD 21

Slide Scientific Advisory Board
Mark Middleton, MD PhD
Dr. Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology, consultant Medical Oncologist at the Oxford Cancer and Haematology Center and Head of the Department of Oncology at the University of Oxford. Dr. Middleton was the Lead Cancer Clinician for the Oxford University Hospitals NHS Foundation Trust (2012 -2017) directed the Early Phase Cancer Trials Unit. He is Director of the Cancer Research UK Oxford Centre and co-leader of the Cancer Theme in the NIHR Biomedical Research Centre.

Dr. Middleton’s research concentrates on the development of new cancer drugs and on the treatment of melanoma and upper gastrointestinal tract cancers. He has overseen the development of internationally leading melanoma and upper GI clinical research groups and establishment of portfolios of early phase radiotherapy and hemato-oncology trials in Oxford. He is involved in the evaluation of novel immunotherapeutics, including pre-clinical development, trial design, proof of mechanism and proof of concept.

He studied medicine at Cambridge and Oxford and trained in medical oncology at the Christie Hospital.

About This Sidebar

  • To edit this sidebar, go to admin backend's Appearance -> Widgets and place widgets into the BlogSidebar Widget Area

 

 

 

 

 

 

 

join our email list

 

 

 

Kineta is a trademark of Kineta, Inc. ©2021 Kineta, Inc. Legal

Back to Top
English
English
Korean